Letter to Shareholders

Dear Shareholders,

I am honored to have to opportunity to comment on the year just ended of DiaSorin, a company which is constantly evolving and which I am very proud of.
This pride is, above all, a consequence of the strategic choices that are the prerequisite for a solid and sustainable growth driving our Group towards new and important objectives we have set for the years to come.
The objectives we are pursuing in all our testing technologies make us an ambitious company that is constantly oriented towards innovation, growth, dedication in providing concrete answers not only to laboratories, but also to clinicians and patients. A company which is aware of its role in innovation and of its ability to rapidly develop high-quality diagnostic solutions.

We are an increasingly international company composed of 3,400 people who employ, every day, their ingenuity, talent, skills and dedication to support projects and products that can help better understand the health conditions of millions of people every year around the globe.

In 2022, our research activities continued to work on ambitious projects able to deeply innovate the diagnostics market. Among these, I would definitely mention the MeMed test that help clinicians differentiate between bacterial and viral infections. This test does not only provide a diagnostic information, but also an indication of the best therapy for the patient, thus providing a valuable tool in the growing global threat posed by antimicrobial resistance.

As regards molecular diagnostics, we continued working to launch on the market the LIAISON® Plex, an innovative multiplexing instrument which allows the detection of a significant number of pathogens on a single sample, providing flexibility on the number of test results and thus lowering the testing cost for laboratories. Or the LIAISON® NES, our future Point-of-Care platform, addressing the growing diagnostic decentralization trend.

These projects, among many others, drove innovation in 2022 and laid the foundations for the future growth of our Group in the years to come.

All this would not be possible, however, without the people who make our company an excellence in the diagnostic world. Researchers, of course, but also all those who, in the different business areas, help DiaSorin grow and expand internationally, creating further conditions for sustainability of our business and our company.

Although Sustainability is a very widely used term in many contexts, it is a necessary condition for the business in which we operate. Our products, in fact, contribute to making health systems and health treatment increasingly sustainable, providing the necessary answers to clinicians about people's state of health and contributing to the improvement of diagnostic solutions for laboratories.

But sustainability, for us in DiaSorin, also means commitment to all the stakeholders who come into contact with us: customers, suppliers, investors, future talents who want to join our future challenges, the local communities where we operate; all this to make “our” DiaSorin even more an example of excellence, innovation, courage and vision, aware of the concrete and tangible impact that our company has on the lives of millions of people every day.

The Chairman
Michele Denegri



A year of challenges and outcomes
Piergiorgio Pedron Chief Financial Officer
Cultural integration: the key challenge of 2022
Stefano Ronchi Senior Corporate Vice President Human Resources
Talent acquisition strategy to overcome the challenges of the future
Valentina Fratto Corporate Talent & Culture Director Gianni Godino Vice President Corporate Human Resources
Predictive models for diagnostics of the future
Fabrizio Bonelli Corporate Vice President & Chief Technology Officer
From diagnostics to care, precision as a method
Giorgio Ghignoni Corporate Vice President Scientific Affairs and Innovation Lead
Sustainable by nature
Riccardo Fava Corporate Vice President Communication & Investor Relations
Excellence at school
Assunta Croce Scientific Communication Manager, Fondazione DiaSorin
Molecular diagnostics
Licensed Technologies
X Close
In 2022, the LIAISON® XL strengthened its international market penetration by leveraging its flexibility, which enables quick and reliable results, and the wide range of both specialty and routine diagnostic tests. The LIAISON® XL platform provides highly-automated solutions, both in stand-alone configuration and through the connection with the main market players’ systems (LIAISON® XL LAS).
X Close

With the end of the pandemic’s acute phase, during which the priority for laboratories was to handle high test volumes for the diagnosis of COVID-19, in 2022 diagnostic tests have been brought back to pre-pandemic levels.
We resumed the LIAISON® XS rollout, a platform designed for hospital laboratories, both public and private, and commercial laboratories by leveraging the features that make it the most suitable platform for laboratories with low and medium specialty test volumes.
LIAISON® XS is also the best solution for diagnostic facilities distributed across the territory: routine testing is performed in a centralized reference "hub", which offers high-throughput processing in a very short time, while specialty testing, for which greater proximity to the patient is deemed necessary, is performed in smaller decentralized diagnostic facilities.

X Close
The LIAISON® MDX platform can be used in association with the Direct Amplification Disc (DAD) for fast, “on demand” results or with the Universal Disc (UD) for routine, screening or high-throughput results.
X Close
The ARIES® platform allows laboratories to control every aspect of the sample-to-answer testing process, improving lab efficiency and workflows through the Universal Assay Protocol that allows multiple sample types and up to 12 different IVD assays.
X Close

The VERIGENE® platform is scalable, allowing throughput customization to meet the size and testing demands of each laboratory. From a single biological sample can rapidly and accurately detect a wide range of infectious pathogens and their associated drug resistance markers.
Panels available on the platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract.

Licensed Technologies
X Close

In 2022, we successfully continued to launch our state-of-the-art xMAP® INTELLIFLEX® platform, developed primarily for the scientific research market. We consider this product as a major growth driver of our Licensed Technologies offer.
The xMAP® INTELLIFLEX® is the modern, compact and robust version of the xMAP® platform, which has been developed by Luminex and is considered the industry’s gold standard for multiplexing of biological tests. The platform enables user to acquire data on two parameters per target nucleic acid or protein, saving time and generating more data with fewer samples. 

Product & Business development


LIAISON® Memed bv®

FDA 510 (k) clearance of the LIAISON ® MeMed BV ® test, developed following the licensing agreement signed with MeMed. The test is the first high throughput blood test to differentiate between viral and bacterial infections.

38 tests on the LIAISON®XS platform

Validation of 38 tests on the LIAISON ® XS platform, bringing the total amount to 86 tests and thus making its menu increasingly relevant for small and medium- sized laboratories.

Partnership with B·R·A·H·M·S

Signing of a partnership with B·R·A·H·M·S, part of Thermo Fisher Scientific, for the development and commercialization of the LIAISON ® B·R·A·H·M·S MR-proADM™, an immunodiagnostic test offering a more precise assessment of disease severity and improving patient management.

Simplexa™ SARS-CoV-2 Variants Direct ASSAY

New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use Only) for the detection of mutations associated with the new COVID Omicron variant.


CE Marking of ARIES ® Flu A/B & RSV+SARS-CoV-2 Assay for the detection of the 4 most common respiratory viruses and their underlying respiratory infections.

Simplexa™ COVID-19 Direct

FDA 510(k) clearance of Simplexa™ COVID-19 Direct test for the detection of SARS-CoV-2 from nasal or nasopharyngeal swabs.

Analyte Specific Reagent (ASR)

Launch of Analyte Specific Reagent (ASR) primer pair to detect the B17R/B18R gene of monkeypox virus, responsible for the health emergency declared by the World Health Organization.

Simplexa™ Congenital CMV Direct

FDA 510(k) clearance of the Simplexa™ Congenital CMV Direct test for the direct detection of Cytomegalovirus DNA in both saliva swab and urine specimens from babies 21 days old or younger.


Extension of collaboration with BARDA (Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services) to support the FDA 510(k) clearance of the LIAISON ® NES.


CE marking of the xMAP ® NxTAG ® GPP Gastrointestinal molecular panel to detect nucleic acids from 16 of the most clinically relevant bacterial, viral, and parasitic pathogens in stool samples on the MAGPIX ® platform.

Simplexa™ COVID-19 & Flu A/B Direct

FDA 510(K) clearance of the Simplexa™ COVID-19 Flu A/B assay to detect Flu A, Flu B, and SARS- CoV-2 viruses in about an hour

sale of the assets related to the Flow Cytometry & Imaging (FCI) business unit

Sale, in February 2023, of the assets related to the Flow Cytometry & Imaging business unit to Cytek ® Biosciences.

Our sustainability strategy


Group key data
> 400

2022 Report